Evidence map›Paper›PMID 42331724›Full record

Trial reportAddiction (Abingdon, England)2026

Collaborative care intervention for risky opioid use among primary care patients: The STOP randomized clinical trial.

Jennifer McNeely, Geetha A Subramaniam, Rebecca Stone, Shayna Mazel, Noa Appleton, Yasna Rostam-Abadi, Amanda M Bunting, Yidan Shi, Travis I Lovejoy, Lillian Gelberg and 9 more

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jennifer McNeelyDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
Geetha A SubramaniamNational Institute on Drug Abuse, National Institutes of Health, North Bethesda, MD, USA.
Rebecca StoneDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
Shayna MazelDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0003-0678-3547
Noa AppletonDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
Yasna Rostam-AbadiDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
Amanda M BuntingDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0002-2103-9655
Yidan ShiDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0002-3190-6724
Travis I LovejoyDepartment of Psychiatry, Oregon Health & Science University, Portland, OR, USA.
Lillian GelbergDepartment of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Donna BeersDivision of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, MA, USA.
Margaret KlineThe Emmes Company, LLC, Rockville, MD, USA.
Song ZhangThe Emmes Company, LLC, Rockville, MD, USA.
Tobie KimThe Emmes Company, LLC, Rockville, MD, USA.
Ashley CaseThe Emmes Company, LLC, Rockville, MD, USA.
Jennifer McCormackThe Emmes Company, LLC, Rockville, MD, USA.
Michael A InczeDivision of General Internal Medicine, Department of Medicine, University of Utah Health, Salt Lake City, UT, USA.ORCID https://orcid.org/0000-0002-1468-930X
Jane M LiebschutzCenter for Research on Health Care, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
STOP trial site principal investigatorsFriends Research Institute, Baltimore, MD, USA.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The Ohio Valley Node of the Clinical Trials Network (CTN-0153)UG1DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI T John WINHUSEN · 2015 to 2026
$42.5M
Project-002UG1DA040309 · NIDA · DARTMOUTH COLLEGE · PI Lisa A. Marsch · 2015 to 2026
$37.9M
TRANSCRANIAL MAGNETIC STIMULATION FOR THE TREATMENT OF METHAMPHETAMINE/COCAINE USE DISORDER (CTN-0108). 9/21/2020-7/17/2023. N01DA-19-2250. TASK ORDER75N95019D00013 · NIDA · THE EMMES COMPANY, LLC · PI MCCORMACK, JENNIFER · 2019 to 2022
$32.8M
SUBTHRESHOLD OPIOID USE DISORDER PREVENTION TRIAL (CTN-0101). AUGUST 1, 2024 TO MARCH 31, 2026. N01DA-22-2253. TASK ORDER NO. 75N95024F00004 (TO20).75N95022D00017 · NIDA · THE EMMES COMPANY, LLC · PI MCCORMACK, JENNIFER · 2022 to 2025
$25.8M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Greater Intermountain Node (CTN-0151)UG1DA049444 · NIDA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Gerald T. Cochran, Gerald T. Cochran · 2019 to 2026
$16.8M
Greater Southern California Node of the Clinical Trials NetworkUG1DA049435 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YIH-ING HSER · 2019 to 2026
$16.7M
Project-008UG1DA049436 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jane M. Liebschutz, Erin L Winstanley · 2019 to 2026
$10.5M
CLC NIH HHS 75N90019D00013CLC NIH HHS 75N90022D00017Department of Veterans Affairs Health Services Research and Development Service Informatics, Decision-Enhancement, and Analytic Sciences Center of Innovation CIN 13-414National Drug Abuse Treatment Clinical Trials Network UG1DA013035National Drug Abuse Treatment Clinical Trials Network UG1DA013732National Drug Abuse Treatment Clinical Trials Network UG1DA015815National Drug Abuse Treatment Clinical Trials Network UG1DA040309National Drug Abuse Treatment Clinical Trials Network UG1DA049435National Drug Abuse Treatment Clinical Trials Network UG1DA049436National Drug Abuse Treatment Clinical Trials Network UG1DA049444NHLBI NIH HHS 75N92022D00017NIDA NIH HHS 75N95019D00013NIDA NIH HHS 75N95022D00017NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013732NIDA NIH HHS UG1 DA015815NIDA NIH HHS UG1 DA040309NIDA NIH HHS UG1 DA049435NIDA NIH HHS UG1 DA049436NIDA NIH HHS UG1 DA049444NIH HHS 75N95021D00013NIH HHS 75N98022D00017NIH HHS 75N99019D00013
6 · The paper itself

Abstract

BACKGROUND AND

aimsIndividuals who engage in illicit or nonmedical opioid use may have elevated risk of health and social consequences, including progression to opioid use disorder (OUD). Preventive interventions to reduce this risk are lacking. This trial tested the impact of a primary care-integrated collaborative care approach for reducing risky opioid use, defined as nonmedical use of prescription opioids or any use of illicit opioids.

designCluster-randomized controlled trial randomized primary care providers (PCPs) and their patients into the Subthreshold Opioid Use Disorder Prevention (STOP) intervention or enhanced usual care (EUC).

settingPrimary care clinics at 5 U.S. sites.

participantsPCPs and their patients were recruited January 2021-May 2023. A total of 119 PCP clusters (STOP = 48, EUC = 51) and 202 patients (STOP = 88, EUC = 114) enrolled. Eligible patients were adults (≥18 years) having current risky opioid use, without moderate-severe OUD. Patient participants were majority female (63.4%), white (70.8%) and non-Hispanic (96.5%), with a mean age of 55.7 [standard deviation (SD) = 12.7] years. At baseline, 63.4% of participants had moderate-severe pain (Brief Pain Inventory) and below average physical (79.2%) and mental (62.4%) health (SF-12).

interventionsThe STOP collaborative care intervention consisted of brief advice from the PCP about reducing risky opioid use, meetings with a clinic-embedded nurse care manager over 12 months and remote health coaching (2-6 sessions). Both groups received primary care treatment as usual and overdose risk reduction materials. MEASUREMENTS: The primary outcome was total days of risky opioid use, recorded from 6 monthly electronic surveys. A key secondary outcome was moderate-severe OUD at 6 and 12 months.

findingsA total of 77 (87.5%) STOP and 107 (93.9%) EUC participants completed the 6-month assessment period. The primary outcome analysis used the Intention-to-Treat sample with multiple imputations of missing data. Mean days of risky opioid use at 180 days were lower in STOP than EUC [12.2 (SD = 27.73) vs. 15.5 (SD = 32.64)]; the difference between groups adjusted for baseline risky opioid use was not statistically significant (rate ratio 0.95, 95% confidence interval = 0.52-1.74). One STOP participant (1.1%) and 13 EUC participants (11.4%) developed moderate-severe OUD at 6 months, and 3 (3.4%) STOP and 6 (5.3%) EUC participants had moderate-severe OUD at 12 months (P < 0.001).

conclusionsThis cluster-randomized controlled trial did not find evidence that the STOP intervention for reducing risky opioid use produced greater reductions over 6 months compared with enhanced usual care, though fewer intervention participants progressed to moderate-severe opioid use disorder. Patients had a high burden of pain and comorbidities that may present challenges to reducing opioid use.

Indexed as

Opioid-Related DisordersPrimary Health CareAdherence InterventionsAdultFemaleHumansMaleMiddle AgedPrescription Drug MisuseUnited Statescollaborative careopioid misuseopioid‐related disorderspainpreventionprimary caresubstance use disorder

Identifiers

PMID42331724
PMCPMC13578841

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.